<DOC>
	<DOCNO>NCT01724359</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability flexible , once-daily dos paliperidone extended-release ( ER ) patient schizophrenia Argentina Colombia previously fail treatment antipsychotic agent .</brief_summary>
	<brief_title>Tolerability , Safety Efficacy Flexibly Dosed Paliperidone ER Patients With Schizophrenia</brief_title>
	<detailed_description>This single arm ( one group patient ) , open-label ( people know identity intervention ) multicenter 6-month study . Throughout study flexible dose paliperidone ER range 3 12 mg/day may use . Flexible dose allow investigator adjust dosage patient base individual need . Patients receive 3 , 6 , 9 12 mg paliperidone ER daily 6 month . The tablet take orally . Adjustment dosage do investigator 's discretion , base individual patient 's clinical response tolerability study drug .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patient meet criteria schizophrenia Patient previously nonacute give adequate dose appropriate oral antipsychotic adequate period time prior enrollment , previous treatment consider unsuccessful due one follow reason : lack efficacy , lack tolerability safety , lack compliance and/or reason switch another antipsychotic medication Patient healthy basis physical examination vital sign screen Women must postmenopausal least 1 year , surgically sterile , abstinent , , sexually active , agree practice effective method birth control entry throughout study Patients clozapine , conventional depot neuroleptic risperidone longacting injection last 3 month Patients serious unstable medical condition , include know clinically relevant laboratory abnormality Patients history current symptom tardive dyskinesia neuroleptic malignant syndrome Patients judge high risk adverse event , violence , selfharm Patients know hypersensitivity paliperidone ER risperidone Patients current use know history ( past 6 month ) substance dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone extended-release ( ER )</keyword>
	<keyword>Antipsychotic agent</keyword>
</DOC>